News >

HER2+ Breast Cancer Paradigm Evolving With Practice-Changing New Options

Brandon Scalea
Published: Tuesday, Apr 09, 2019

Mark D. Pegram, MD

Mark D. Pegram, MD
Breast cancer treatment has evolved dramatically over the past 2 decades, said Mark D. Pegram, MD, and several approaches are emerging for those with HER2-positive metastatic disease in the form of new antibody-drug conjugates (ADCs) and small molecule inhibitors.

, Pegram highlighted data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and shed light on emerging agents that are showing promise in the pipeline.

OncLive: What have been the most exciting data in the HER2-positive breast cancer space?

Pegram: There has never been a more exciting time to be in the area of clinical research and clinical investigation for HER2-positive breast cancer. Some might say that there is not much work left to be done, particularly in early stages of HER2-positive breast cancer, because of the results of the adjuvant trastuzumab plus chemotherapy trials. These studies, from over a decade ago, were so spectacular that some people feel the “heavy lifting” is over.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication